LYZZ Capital
VC Fund
Shanghai, China
LYZZ Capital is a venture capital firm specialized in seed, early, and expansion stage venture investments.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries LYZZ Capital invests in
Stages LYZZ Capital invests in
Countries LYZZ Capital invests in
Investment Focus
Industry
- Biotechnology 10 (67%)
- Health Care 5 (33%)
- Therapeutics 5 (33%)
- Biopharma 3 (20%)
- Pharmaceutical 3 (20%)
Stage
- Series A 5 (33%)
- Series B 5 (33%)
- Series C 2 (13%)
- Series D 1 (7%)
- Funding Round 1 (7%)
Country
- United States 7 (47%)
- China 5 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Onchilles Pharma
|
Onchilles Pharma is a biotechnology company developing first-in-class biologics therapies for the treatment of cancer. The company's drug selectively targets cancer cells and is non-toxic to normal cells and tissues, helping medical professionals treat cancer patients efficiently.It was founded in 2017 and is headquartered in San Diego,California. | $25M / Series A / Nov 07, 2025 | |
Wugen
|
Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cellmalignancies. | $115M / Series C / Aug 27, 2025 | |
MojiaBio
|
Mojia Bioscience is a biotechnology company. | $80M / Series B / Jun 22, 2022 | |
|
SUSTAO
|
SUSTAO is a manufacturer of consumables that meet the technical requirements of medical robots. | Series A / Apr 29, 2022 | |
OncoMyx Therapeutics
|
OncoMyx Therapeutics develops oncolytic immunotherapies called myxoma (MYXV) to assist in creating an immune response and treat cancer. Its myxoma virus (MYXV) platform targets hematologic and solid tumors with a unique oncolytic virus called myxoma and a novel patented systemic delivery approach which can be carried systemically by humanleukocytes where it can then infect tumor cells.The company was founded in 2018 and is headquartered in Phoenix, Arizona. | $50M / Series B / Dec 09, 2021 | |
Viron
|
OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. The company's MYXV platform, is poised to be a best-in-class OV approach. The company assembled the top OV team around MYXV to advance a pipeline of oncology therapeutics for the benefit ofcancer patients. | $50M / Series B / Dec 08, 2021 | |
|
Wugen
|
Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cellmalignancies. | $172M / Series B / Jul 15, 2021 | |
Neurelis
|
Neurelis is a specialty pharmaceutical company, licenses, develops, and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market. It provides a differentiated approach to target unmet medical needs. Their application of novel technologies is designed to enhance the therapeutic benefit and patient care.Thecompany was incorporated in 2007 and is based in Encinitas, California. | $114M / Series D / Mar 10, 2021 | |
Jumpcode Genomics
|
JUMPCODE's CRISPR-mediated rRNA depletion kits remove nucleic acids from sequencing workflows to improve sensitivity and performance.CRISPRclean is a proprietary technology that utilizes the CRISPR/CAS system to cut through the noise by removing unwanted nucleic acid molecules from sequencing libraries while preserving therepresentational integrity of the non-targeted sequences.Keith Brown founded the company in Carlsbad, California in 2016. | $21M / Series B / Jan 20, 2021 | |
|
Onchilles Pharma
|
Onchilles Pharma is a biotechnology company developing first-in-class biologics therapies for the treatment of cancer. The company's drug selectively targets cancer cells and is non-toxic to normal cells and tissues, helping medical professionals treat cancer patients efficiently.It was founded in 2017 and is headquartered in San Diego,California. | $7M / Series A / Jul 10, 2020 | |
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does LYZZ Capital invest in?
LYZZ Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did LYZZ Capital last invest?
The most recent investment recorded for LYZZ Capital closed in Nov 2025. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
